Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.
A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of rapamycin (mTOR) inhibitor everolimus, initially randomized to placebo (but had disease progression after 3 months) and crossed over to everolimus at time of unblinding. The patient had stable disease after 8 weeks (two cycles) of everolimus that was maintained until 28 months of therapy, at which time the patient had achieved a partial response. This case illustrates the potential for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis, to derive long-term benefit from everolimus when used in a manner consistent with its approved indication (after TKI therapy with sunitinib or sorafenib).
Molina
Ana M
AM
Genitourinary Service, Division of Medical Oncology and the Department of Medical Imaging, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Ginsberg
Michelle S
MS
Motzer
Robert J
RJ
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D017326:Clinical Trials, Phase III as Topic; D000068338:Everolimus; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D006973:Hypertension / Q000150:complications; D007211:Indoles / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D011758:Pyrroles / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy / Q000379:methods*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib; D020123:Sirolimus